Mr. Wood
Banned
- Joined
- Oct 4, 2013
- Messages
- 26,961
- Reaction score
- 5,127
Novartis delivered strong H1 performance. FY 2020 guidance confirmed
at higher end for core operating income and lower end for sales
July 21, 2020
at higher end for core operating income and lower end for sales
July 21, 2020
In July, Novartis launched a first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19. The new portfolio of 15 medicines from the Sandoz division addresses urgent unmet needs of low and lower middle income countries to treat patients with COVID-19 symptoms. The portfolio will be sold at no profit to governments in up to 79 eligible low and lower middle income countries during the pandemic and until a vaccine or curative treatment is available.
